Coronavirus Live Count Map India
remove_red_eye 682 Views
COVID-19 Vaccine Updates
The purpose of a recent study was to ascertain the efficacy and safety of dapagliflozin on kidney outcomes in all patients who are taking this drug, as well as in prespecified subgroups of participants defined by baseline estimated glomerular filtration rate (eGFR).
This study analyzed participants of the Dapagliflozin in Respiratory Failure in Patients with COVID-19 (DARE-19) trial – a randomized controlled trial that included 1,250 patients (with eGFR <60 ml/min/1.73 m3) hospitalized due to coronavirus disease 2019 (COVID-19), who had cardiometabolic risk factors to dapagliflozin or placebo.
The results showed that the effect of dapagliflozin compared to placebo on the time to new or worsened organ dysfunction or death and a hierarchical composite endpoint of recovery (change in clinical status by day-30) was similar across eGFR subgroups – eGFR <60 and ≥60 ml/min per 1.73 m2. The same was true for the composite kidney outcome – a composite of acute kidney injury (AKI), kidney replacement therapy (KRT), or death. In addition, the effects of dapagliflozin on AKI also remained unchanged among the eGFR subgroups. Moreover, the drug was well-tolerated in all participants.
Thus, in hospitalized COVID-19 patients, the effects of dapagliflozin remained consistent concerning the kidney outcomes among those with eGFR below and above 60 ml/min per 1.73 m2. Furthermore, the drug was well-tolerated and did not increase the risk of AKI in these subjects.
Source: Clinical Journal of the American Society of Nephrology. 2022 Apr 28;CJN.14231021. doi: 10.2215/CJN.14231021.